12 Best Penny Stocks to Invest in According to the Media

Page 4 of 11

8. Karyopharm Therapeutics Inc. (NASDAQ:KPTI

Share Price (As of January 3): $0.78

Number of Hedge Fund Holders: 19

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a commercial-stage pharmaceutical company, focused on the discovery, development, and commercialization of drugs for the treatment of cancer and other diseases. The company is developing and commercializing small molecule Selective Inhibitors of Nuclear Export (SINE) compounds that help block cancer cells and stop them from growing.

XPOVIO or selinexor is the lead product of Karyopharm Therapeutics Inc. (NASDAQ:KPTI), which helps in the treatment of adult patients with plasma cells that cause cancer. Similar to selinexor, the company is working on an oral SINE compound, eltanexor, which will potentially add to the company’s sales.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) achieved its third consecutive quarter of net product revenue growth during the third quarter of 2024. The net US XPOVIO revenue sustained its growth from a year ago and posted $29.5 million for Q3. Whereas, the net revenue reached $38.8 million in Q3, up from $36 million from a year ago. The strong commercial performance of XPOVIO has been a key contributor for Karyopharm. Moreover, the company has expanded its reimbursement and regulatory approvals for its lead assets in Italy and France. With further developments of its candidates in ongoing phase three studies, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) looks like a solid penny stock to invest in.

Page 4 of 11